Recurrent BRCA1 and BRCA2 mutations in Mexican women with breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 3, 2015, Pages 498-505

  Torres Mejía, Gabriela ^a   Royer, Robert ^b   Llacuachaqui, Marcia ^b   Akbari, Mohammad R ^b   Giuliano, Anna R ^c   Martínez Matsushita, Louis ^a   Angeles Llerenas, Angélica ^a   Ortega Olvera, Carolina ^a   Ziv, Elad ^d,e,f   Lazcano Ponce, Eduardo ^a   Phelan, Catherine M ^c   Narod, Steven A ^b  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b UNIVERSITY OF TORONTO   (Canada)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d Institute for Human Genetics   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; GENOMIC DNA;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; COPY NUMBER VARIATION; FEMALE; GENETIC SCREENING; GERMLINE MUTATION; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MEXICAN; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RECURRENT MUTATION; AGED; BREAST NEOPLASMS; CASE CONTROL STUDY; CLINICAL TRIAL; GENETICS; MEXICO; MIDDLE AGED; MULTICENTER STUDY; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; MEXICO; MIDDLE AGED;

EID: 84927714699     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0980     Document Type: Article

References (63)

1. Pan American Health Organization. Health in the Americas, Washington D.C.: PAHO; PAHO Scientific Publication 1998;5691.
2. Parkin DM, Whelan SL, Ferlay J, Raymond I, Young Jeds., et al. Cancer incidence in five continents, volume VII. Lyon, France: International Agency for Research on Cancer. IARC Scientific Publication 143;1997.
3. Curado MP, Edwards B, Shin HR, Ferlay J, Heanue M, Boyle P, et al. Cancer incidence in five continents, volume IX. Lyon, France: International Agency for Research on Cancer. IARC Scientific Publication; 2008.
4. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50.
5. Chavarri-Guerra Y, Villarreal-Garza C, Liedke PE, Knaul F, Mohar A, Finkelstein DM, et al. Breast cancer in Mexico: a growing challenge to health and the health system. Lancet Oncol 2012;138:e335-43.
6. Knaul FM, Nigenda G, Lozano R, Arreola-Ornelas H, Langer A, Frenk J, et al. Breast cancer in Mexico: a pressing priority. Reprod Health Matters 2008; 16:113-23.
7. de la Vara-Salazar E, Suarez-Lopez L, Angeles-Llerenas A, Torres-Mejía G, Lazcano-Ponce E. Breast cancer mortality trends in Mexico, 1980-2009. Salud Publica Mex 2011;53:385-93.
8. Bosetti C, Rodríguez T, Chatenoud L, Bertuccio P, Levi F, Negri E, et al. Trends in cancer mortality in Mexico, 1981-2007. Eur J Cancer Prev 2011;20:355-63.
9. Stankov A, Bargallo-Rocha JE, Silvio AN, Ramirez MT, Stankova-Ninova K, Meneses-Garcia A, et al. Prognostic factors and recurrence in breast cancer: experience at the national cancer institute of Mexico. ISRN Oncol 2012;2012:825258.
10. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
11. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
12. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-89.
13. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20: 1480-90.
14. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145-58.
15. Shih HA, Couch FJ, Nathanson KL, Blackwood MA, Rebbeck TR, Armstrong KA, et al. BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol 2002;20:994-9.
16. Kurian AW. BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Curr Opin Obstet Gynecol 2010;22: 72-8.
17. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
18. Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999;91:1241-7.
19. Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 2010;28:387-91.
20. Phelan CM, Kwan E, Jack E, Li S, Morgan C, Aube J, et al. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. Hum Mutat 2002;20:352-7.
21. Verhoog L, van den Ouweland AM, Berns EC, van Veghel-Plandsoen MM, van Staveren IL, Wagner A, et al. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur J Cancer 2001;37:2082-90.
22. Ghadirian P, Robidoux A, Zhang P, Royer R, Akbari M, Zhang S, et al. The contribution of founder mutations to early-onset breast cancer in French-Canadian women. Clin Genet 2009;76:421-6.
23. Tulinius H, Olafsdottir GH, Sigvaldason H, Arason A, Barkardottir RB, Egilsson V, et al. The effect of a single BRCA2 mutation on cancer in Iceland. J Med Genet 2002;39:457-62.
24. Harboe TL, Eiberg H, Kern P. A high frequent BRCA1 founder mutation identified in the Greenlandic population. Fam Cancer 2009;8:413-9.
25. Gorski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet 2000;66:1963-8.
26. Sokolenko AP, Rozanov ME, Mitiushkina NV, Sherina NY, Iyevleva AG, Chekmariova EV, et al. Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. Fam Cancer 2007;6:281-6.
27. Uglanitsa N, Oszurek O, Uglanitsa K. The contribution of founder mutations in BRCA1 to breast cancer in Belarus. Clin Genet 2010;78:377-80.
28. Elsakov P, Kurtinaitis J, Petraitis S, Ostapenko V, Razumas M, Razumas T, et al. The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania. Clin Genet 2010;78:373-6.
29. Tikhomirova L, Sinicka O, Smite D, Eglitis J, Hodgson SV, Stengrevics A, et al. High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia. Fam Cancer 2005;4:77-84.
30. Hamel N, Feng BJ, Foretova L, Stoppa-Lyonnet D, Narod SA, Imyanitov E, et al. On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet 2011;19:300-6.
31. Armakolas A, Ladopoulou A, Konstantopoulou I, Pararas B, Gomatos IP, Kataki A, et al. BRCA2 gene mutations in Greek patients with familial breast cancer. Hum Mutat 2002;19:81-2.
32. Koumpis C, Dimitrakakis C, Antsaklis A, Royer R, Zhang S, Narod SA, et al. Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece. Hered Cancer Clin Pract 2011;15:9-10.
33. Weitzel JN, Lagos V, Blazer KR, Nelson R, Ricker C, Herzog J, et al. Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 2005;14:1666-71.
34. Weitzel JN, Lagos VI, Herzog JS, Judkins T, Hendrickson B, Ho JS, et al. Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 2007;16:1615-20.
35. Torres D, Rashid MU Colombian Breast Cancer Study Group (COLBCS) Seidel-Renkert A, Weitzel JN, Briceno I, et al. Absence of the BRCA1 del (exons 9-12) mutation in breast/ovarian cancer families outside of Mexican Hispanics. Breast Cancer Res Treat 2009;117:679-81.
36. Weitzel JN, Clague J, Martir-Negron A, Ogaz R, Herzog J, Ricker C, et al. Prevalence and type of BRCA mutations in hispanics undergoing genetic cancer risk assessment in the Southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol 2013;31:210-6.
37. Vogel KJ, Atchley DP, Erlichman J, Broglio KR, Ready KJ, Valero V, et al. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol 2007;25:4635-41.
38. John EM, Miron A, Gong G, Phipps AI, Felberg A, Li FP, et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 2007;298:2869-76.
39. Torres D, Rashid MU, Gil F, Umana A, Ramelli G, Robledo JF, et al. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat 2007;103:225-32.
40. Gomes MC, Costa MM, Borojevic R, Monteiro AN, Vieira R, Koifman S, et al. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 2007;103:349-53.
41. Donenberg T, Lunn J, Curling D, Turnquest T, Krill-Jackson E, Royer R, et al. A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. Breast Cancer Res Treat 2011;125:591-6.
42. Jara L, Ampuero S, Santibanez E, Seccia L, Rodríguez J, Bustamante M, et al. BRCA1 and BRCA2 mutations in a South American population. Cancer Genet Cytogenet 2006;166:36-45.
43. Ruiz-Flores P, Sinilnikova OM, Badzioch M, Calderon-Garciduenas AL, Chopin S, Fabrice O, et al. BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico. Hum Mutat 2002;20: 474-5.
44. Vidal-Millan S, Taja-Chayeb L, Gutierrez-Hernandez O, Ramírez Ugalde MT, Robles-Vidal C, Bargallo-Rocha E, et al. Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients. Eur J Gynaecol Oncol 2009;30:527-30.
45. Calderon-Garciduenas AL, Ruiz-Flores P, Cerda-Flores RM, Barrera-Saldana HA. Clinical follow up of mexican women with early onset of breast cancer and mutations in the BRCA1 and BRCA2 genes. Salud Publica Mex 2005;47:110-5.
46. Vaca-Paniagua F, Alvarez-Gomez RM, Fragoso-Ontiveros V, Vidal-Millan S, Herrera LA, Cantu D, et al. Full-exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer. PLoS ONE2012;7:5.
47. Narod SA. Screening for BRCA1 and BRCA2 mutations in breast cancer patients from Mexico: the public health perspective. Salud Publica Mex 51 Suppl 2009;2:s191-6.
48. Angeles-Llerenas A, Ortega-Olvera C, Perez-Rodríguez E, Esparza-Cano JP, Lazcano-Ponce E, Romieu I, et al. Moderate physical activity and breast cancer risk: the effect of menopausal status. Cancer Causes Control 2010;21:577-86.
49. Beasley JM, Coronado GD, Livaudais J, Angeles-Llerenas A, Ortega-Olvera C, Romieu I, et al. Alcohol and risk of breast cancer in Mexican women. Cancer Causes Control 2010;21:863-70.
50. Sânchez-Zamorano LM, Flores-Luna L, Angeles-Llerenas A, Romieu I, Lazcano-Ponce E, Miranda-Hernandez H, et al. Healthy lifestyle on the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2011;20: 912-22.
51. Fejerman L, Romieu I, John EM, Lazcano-Ponce E, Huntsman S, Beckman KB, et al. European ancestry is positively associated with breast cancer risk in Mexican women. Cancer Epidemiol Biomarkers Prev 2010;19:1074-82.
52. Kuperstein G, Foulkes WD, Ghadirian P, Hakimi J, Narod SA. A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes. Clin Genet 2000;57:213-20.
53. Alter BP, Rosenberg PS, Brody LC. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet 2007;44:1-9.
54. Breast Cancer Information Core [Internet]. Bethesda: NHGRI; 2013 [cited 2013 June 19]. Available from: http://research.nhgri.nih.gov/bic/
55. Osorio A, Barroso A, Martínez B, Cebrian A, San Roman JM, Lobo F, et al. Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. Br J Cancer 2000;82:1266-70.
56. Díez O, Osorio A, Robledo M, Barroso A, Domènech M, Cortes J, et al. Prevalence of BRCA1 and BRCA2 Jewish mutations in Spanish breast cancer patients. Br J Cancer 1999;79:1302-3.
57. Velez C, Palamara PF, Guevara-Aguirre J, Hao L, Karafet T, Guevara-Aguirre M, et al. The impact of Converso Jews on the genomes of modern Latin Americans. Hum Genet 2012;131:251-63.
58. Mullineaux LG, Castellano TM, Shaw J, Axell L, Wood ME, Diab S, et al. Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado. Cancer 2003;98:597-602.
59. Myers K, Davies SM, Harris RE, Spunt SL, Smolarek T, Zimmerman S, et al. The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations. Pediatr Blood Cancer 2012;58:462-5.
60. Reid S, Renwick A, Seal S, Baskcomb L, Barfoot R, Jayatilake H, et al. Familial Wilms Tumour Collaboration. Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumor. J Med Genet 2005;42:147-51.
61. Rahman N, Scott RH. Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. Hum Mol Genet 2007;16 Spec No 1:R60-6. Review.
62. Domchek SM, Tang JB, Stopfer J, Lilli DR, Hamel N, Tischkowitz M, et al. Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. Cancer Discov 2013;3:399-405.
63. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012;21:134-47.